The research company Aptahem intends to carry out a rights issue of up to 21 million shares, corresponding to approximately SEK 13.8 million before costs. The subscription price is set at SEK 0.66 per share, corresponding to a discount of 21.6 percent compared with the volume-weighted average price during the period March 13–26. The subscription period runs April 10–24. The purpose is to strengthen financial flexibility and enable continued development of the drug candidate Apta-1 within two strategic main areas."Our focus going forward is clear - to establish partnerships with industrial and financial players that can contribute both capital and expertise to accelerate the development. Interest in Apta-1 has gradually strengthened, and we are now conducting more in-depth dialogues with potential partners. In parallel, we are actively working to broaden our international investor base and evaluate opportunities for non-dilutive financing," comments CEO Mikael Lindström.